Publikationen, an denen er mitarbeitet Marcos González Díaz (17)

2023

  1. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

2020

  1. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

    Blood Cancer Journal, Vol. 10, Núm. 2

  2. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

2016

  1. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

    Nature Communications, Vol. 7

  2. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations

    Oncotarget, Vol. 7, Núm. 49, pp. 80916-80924

2015

  1. CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

    Haematologica

2011

  1. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy

    Haematologica, Vol. 96, Núm. 10, pp. 1470-1477

2010

  1. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

    Haematologica, Vol. 95, Núm. 3, pp. 424-431

2008

  1. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

    Blood, Vol. 112, Núm. 8, pp. 3130-3134

2007

  1. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia

    British Journal of Haematology, Vol. 136, Núm. 4, pp. 590-596

  2. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies

    Leukemia, Vol. 21, Núm. 7, pp. 1413-1422

2004

  1. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group

    Blood, Vol. 103, Núm. 4, pp. 1237-1243

2002

  1. Two new molecular PML-RARalpha variants: implications for the molecular diagnosis of APL.

    Haematologica, Vol. 87, Núm. 8

2001

  1. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracycline-based protocol. A report from the spanish group PETHEMA

    Haematologica, Vol. 86, Núm. 8, pp. 807-813

  2. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: A study of the PETHEMA group

    British Journal of Haematology, Vol. 114, Núm. 1, pp. 99-103

  3. Variability in the levels of PML-RARα fusion transcripts detected by laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocols

    Haematologica, Vol. 86, Núm. 6, pp. 570-576

1999

  1. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia

    Blood, Vol. 94, Núm. 9, pp. 3015-3021